Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 217,275,335 papers from all fields of science
Search
Sign In
Create Free Account
alteplase
Known as:
T-Plasminogen Activator
, Tissue Activator D 44
, TPA
Expand
A recombinant therapeutic agent which is chemically identical to or similar to endogenous tissue plasminogen activator (tPA). tPA is a serine…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
38 relations
Narrower (19)
Actilyse
Activase
D-K2P
Fb-Fb-CF
Expand
Drug Allergy
In Blood
Increased Thrombolysis [PE]
Intracranial Embolism and Thrombosis
Expand
Broader (1)
Fibrinolytic Agents
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
W. Powers
,
A. Rabinstein
,
+16 authors
D. Tirschwell
Stroke
2018
Corpus ID: 4972922
Background and Purpose— The purpose of these guidelines is to provide an up-to-date comprehensive set of recommendations for…
Expand
Highly Cited
2015
Highly Cited
2015
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.
J. Saver
,
M. Goyal
,
+20 authors
R. Jahan
New England Journal of Medicine
2015
Corpus ID: 6570411
BACKGROUND Among patients with acute ischemic stroke due to occlusions in the proximal anterior intracranial circulation, less…
Expand
Highly Cited
2008
Highly Cited
2008
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
W. Hacke
,
M. Kaste
,
+11 authors
D. Toni
New England Journal of Medicine
2008
Corpus ID: 12016921
BACKGROUND Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and…
Expand
Highly Cited
2004
Highly Cited
2004
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials
W. Hacke
,
G. Donnan
,
+21 authors
Ecass Trials Investigators
The Lancet
2004
Corpus ID: 22354930
Highly Cited
1999
Highly Cited
1999
Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial
A. Furlan
,
R. Higashida
,
+9 authors
F. Rivera
1999
Corpus ID: 11008194
ContextIntravenous tissue-type plasminogen activator can be beneficial to some patients when given within 3 hours of stroke onset…
Expand
Highly Cited
1998
Highly Cited
1998
Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators…
W. Hacke
,
M. Kaste
,
+10 authors
P. Trouillas
The Lancet
1998
Corpus ID: 25785449
BACKGROUND Thrombolysis for acute ischaemic stroke has been investigated in several clinical trials, with variable results. We…
Expand
Highly Cited
1998
Highly Cited
1998
Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
W. Hacke
,
M. Kaste
,
+10 authors
P. Trouillas
The Lancet
1998
Corpus ID: 53549605
Highly Cited
1996
Highly Cited
1996
Tissue plasminogen activator for acute ischemic stroke.
Koroshetz Wj
New England Journal of Medicine
1996
Corpus ID: 25812408
BACKGROUND Thrombolytic therapy for acute ischemic stroke has been approached cautiously because there were high rates of…
Expand
Highly Cited
1995
Highly Cited
1995
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
J. Grotta
,
M. Kothari
,
+6 authors
P. O'Byrne
1995
Corpus ID: 74597570
Highly Cited
1993
Highly Cited
1993
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
M. Simoons
,
E. Topol
,
+12 authors
J. Hampton
New England Journal of Medicine
1993
Corpus ID: 20322138
BACKGROUND The relative efficacy of streptokinase and tissue plasminogen activator and the roles of intravenous as compared with…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE